A 6-month prospective study of tixagevimab and cilgavimab (Evusheld) in immunosuppressed pwNID in preventing breakthrough COVID-19 infections
Latest Information Update: 12 Apr 2023
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Ad26.COV2 S; Elasomeran; Tozinameran
- Indications COVID 2019 infections
- Focus Therapeutic Use
- 12 Apr 2023 New trial record
- 25 Feb 2023 Results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023